| HOME >> BIOLOGY >> TECHNOLOGY |
Costs of commercial revenues were $303,000 for 2012 compared to $219,000 for 2011. Costs of commercial revenues were $100,000 for the fourth quarter of 2012 compared to $66,000 for the fourth quarter of 2011. These increases are consistent with the corresponding increases in commercial revenues. These amounts are comprised entirely of royalty payments related to certain in-licensed technologies.Research and development expenses, including stock-based compensation expense, were relatively flat at $28.6 million for 2012 compared to $28.7 million for 2011. Research and development expenses, including stock-based compensation expense, were $7.2 million for the fourth quarter of 2012 compared to $7.1 million for the fourth quarter of 2011.
General and administrative expenses, including stock-based compensation expense, were relatively flat at $11.6 million for 2012 compared to $11.5 million for 2011. General and administrative expenses, including stock-based compensation expense, were $3.1 million for the fourth quarter of 2012 compared to $3.2 million for the fourth quarter of 2011.
The net loss for 2012 was $0.23 per share, compared to $0.22 per share for 2011. The net loss for the fourth quarter of 2012 was $0.06 per share compared to a net loss of $0.04 per share for the fourth quarter of 2011.
Financial Outlook:"Senomyx ended 2012 with a healthy balance sheet, including nearly $42 million in cash and no debt. For the full year 2012, the Company delivered results in-line with financial guidance," stated Tony Rogers, Senior Vice President and Chief Financial Officer.
For the full year 2013, Senomyx expects:
| SOURCE Senomyx Copyright©2012 PR Newswire. All rights reserved |